BridgeBio Oncology Therapeutics, Inc. President and CEO Pedro Beltran filed a Form 4 on November 20, 2026, disclosing the sale of 1,870 shares of common stock on November 18, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting Person: Pedro Beltran, President and CEO, and Director of BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT)
  • Shares Sold: 1,870 shares of common stock disposed of on November 18, 2026, with transaction code S
  • Weighted Average Price: $1.841 per share, with individual transactions ranging from $1.80 to $1.94
  • Remaining Ownership: 41,659 shares of common stock held directly following the reported transaction
  • 10b5-1 Plan: The sale was effected pursuant to a Rule 10b5-1 sales plan adopted by Beltran on August 19, 2026

Details of Pedro Beltran's November 2026 Share Sale at BridgeBio Oncology Therapeutics

According to the Form 4 filed with the SEC on November 20, 2026, Pedro Beltran, who serves as both President and CEO and as a Director of BridgeBio Oncology Therapeutics, Inc., disposed of 1,870 shares of the company's common stock on November 18, 2026. The filing identifies NASDAQ:BBOT as the issuer. The transaction carried code "S," indicating a sale, and was reported as a direct ownership transaction.

The filing disclosed that the price reported is a weighted average of $1.841 per share. According to the filing's explanation of responses, "the shares were sold in multiple transactions at prices ranging from $1.80 to $1.94." The filing further states that Beltran "undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."

The filing notes that this transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Beltran on August 19, 2026. The Form 4 also indicates that the transaction checkbox for Rule 10b5-1(c) has been checked, signifying the sale was made under a pre-arranged written plan. Following the reported sale, Beltran's direct beneficial ownership in BridgeBio Oncology Therapeutics common stock stands at 41,659 shares, according to the filing. The Form 4 was signed by Aaron Chan as Attorney-in-Fact on November 20, 2026.

What Was Disclosed

Pedro Beltran, President, CEO, and Director of BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT), disclosed the sale of 1,870 common shares on November 18, 2026, at a weighted average price of $1.841, under a Rule 10b5-1 plan adopted August 19, 2026, leaving him with 41,659 shares held directly.